BridgeBio have significantly boosted its development of a novel therapy for amyloid heart disease, utilizing the compound. Preliminary patient data suggests promising improvements for individuals affected from a https://attr-cm472579.ambien-blog.com/49019918/company-advances-cardiac-amyloidosis-treatment-through-the-therapy